Last updated on October 2018

Tenofovir to Prevent HBV Reactivation


Brief description of study

The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma or CLL/SLL. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.

Clinical Study Identifier: NCT02186574

Find a site near you

Start Over